GLP1R and obesity due to melanocortin 4 receptor deficiency: In the past 20 years, the discovery and development of GLP-1 receptor agonists and DPP-4 inhibitors have markedly advanced pharmacological treatment options for obesity and diabetes [5,6], with novel compounds continuing to emerge in the pharmaceutical pipeline [7].